Inhibition of GSK-3 Ameliorates Aβ Pathology in an Adult-Onset Drosophila Model of Alzheimer's Disease

Aβ peptide accumulation is thought to be the primary event in the pathogenesis of Alzheimer's disease (AD), with downstream neurotoxic effects including the hyperphosphorylation of tau protein. Glycogen synthase kinase-3 (GSK-3) is increasingly implicated as playing a pivotal role in this amyloid cascade. We have developed an adult-onset Drosophila model of AD, using an inducible gene expression system to express Arctic mutant Aβ42 specifically in adult neurons, to avoid developmental effects. Aβ42 accumulated with age in these flies and they displayed increased mortality together with progressive neuronal dysfunction, but in the apparent absence of neuronal loss. This fly model can thus be used to examine the role of events during adulthood and early AD aetiology. Expression of Aβ42 in adult neurons increased GSK-3 activity, and inhibition of GSK-3 (either genetically or pharmacologically by lithium treatment) rescued Aβ42 toxicity. Aβ42 pathogenesis was also reduced by removal of endogenous fly tau; but, within the limits of detection of available methods, tau phosphorylation did not appear to be altered in flies expressing Aβ42. The GSK-3–mediated effects on Aβ42 toxicity appear to be at least in part mediated by tau-independent mechanisms, because the protective effect of lithium alone was greater than that of the removal of tau alone. Finally, Aβ42 levels were reduced upon GSK-3 inhibition, pointing to a direct role of GSK-3 in the regulation of Aβ42 peptide level, in the absence of APP processing. Our study points to the need both to identify the mechanisms by which GSK-3 modulates Aβ42 levels in the fly and to determine if similar mechanisms are present in mammals, and it supports the potential therapeutic use of GSK-3 inhibitors in AD.

[1]  R. Hen,et al.  Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. , 2001, The EMBO journal.

[2]  T. Saido,et al.  Metabolic regulation of brain Abeta by neprilysin. , 2001, Science.

[3]  L. Marlow,et al.  Alzheimer's Disease β-Amyloid Peptide Is Increased in Mice Deficient in Endothelin-converting Enzyme* , 2003, The Journal of Biological Chemistry.

[4]  Christina A. Wilson,et al.  GSK-3α regulates production of Alzheimer's disease amyloid-β peptides , 2003, Nature.

[5]  F. van Leuven,et al.  Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice. , 2008, The American journal of pathology.

[6]  W. Bender,et al.  A Drosophila model of Parkinson's disease , 2000, Nature.

[7]  B. Lu,et al.  PAR-1 Kinase Plays an Initiator Role in a Temporally Ordered Phosphorylation Process that Confers Tau Toxicity in Drosophila , 2004, Cell.

[8]  J. Shulman,et al.  The role of PAR-1 in regulating the polarised microtubule cytoskeleton in the Drosophila follicular epithelium , 2003, Development.

[9]  D. Selkoe,et al.  Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. , 2003, Annual review of pharmacology and toxicology.

[10]  F. LaFerla,et al.  Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. , 2007, The American journal of pathology.

[11]  Christina A. Wilson,et al.  GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. , 2003, Nature.

[12]  Stephan J. Froggett,et al.  Targeted Expression of Truncated Glued Disrupts Giant Fiber Synapse Formation in Drosophila , 1999, The Journal of Neuroscience.

[13]  D. Shepherd,et al.  Aβ exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer's disease , 2010, Experimental Neurology.

[14]  V. Pantesco,et al.  Drosophila shaggy kinase and rat glycogen synthase kinase-3 have conserved activities and act downstream of Notch , 1993, Nature.

[15]  Jason Eriksen,et al.  A decade of modeling Alzheimer's disease in transgenic mice. , 2006, Trends in genetics : TIG.

[16]  J. Ávila,et al.  Characterization of a double (amyloid precursor protein-tau) transgenic: Tau phosphorylation and aggregation , 2005, Neuroscience.

[17]  M. Mercken,et al.  Presenilin Redistribution Associated with Aberrant Cholesterol Transport Enhances β-Amyloid Production In Vivo , 2003, The Journal of Neuroscience.

[18]  Huaxi Xu,et al.  Effects of endogenous β‐amyloid overproduction on tau phosphorylation in cell culture , 2006, Journal of neurochemistry.

[19]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[20]  A. Harwood,et al.  Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. , 2001, Biochemical and biophysical research communications.

[21]  Joshua M. Shulman,et al.  Tauopathy in Drosophila: Neurodegeneration Without Neurofibrillary Tangles , 2001, Science.

[22]  Kanae Iijima-Ando,et al.  Tau Ser262 phosphorylation is critical for Abeta42-induced tau toxicity in a transgenic Drosophila model of Alzheimer's disease. , 2010, Human molecular genetics.

[23]  Simon Lovestone,et al.  Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells , 1994, Current Biology.

[24]  W. Noble,et al.  Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. J. Allen,et al.  Making an escape: development and function of the Drosophila giant fibre system. , 2006, Seminars in cell & developmental biology.

[26]  S. Lovestone,et al.  GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila , 2004, Molecular Psychiatry.

[27]  A. Bejsovec,et al.  Cellular mechanisms of wingless/Wnt signal transduction. , 1999, Current topics in developmental biology.

[28]  René Hen,et al.  Decreased nuclear β‐catenin, tau hyperphosphorylation and neurodegeneration in GSK‐3β conditional transgenic mice , 2001 .

[29]  L. Pennanen,et al.  Different tau epitopes define Aβ42-mediated tau insolubility , 2005 .

[30]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[31]  T. Aigaki,et al.  Insulin‐degrading enzyme antagonizes insulin‐dependent tissue growth and Aβ‐induced neurotoxicity in Drosophila , 2010, FEBS letters.

[32]  T. Dale,et al.  Glycogen synthase kinase 3: A key regulator of cellular fate , 2007, Cellular and Molecular Life Sciences.

[33]  Benjamin H. White,et al.  A conditional tissue-specific transgene expression system using inducible GAL4 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  C. Duijn,et al.  High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands. , 1999, American journal of human genetics.

[35]  D. Selkoe,et al.  Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Götz,et al.  Different tau epitopes define Abeta42-mediated tau insolubility. , 2005, Biochemical and Biophysical Research Communications - BBRC.

[37]  J. Woodgett,et al.  Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinase , 1992, Neuroscience Letters.

[38]  K. Irvine,et al.  In vivo regulation of Yorkie phosphorylation and localization , 2008, Development.

[39]  D. Chuang,et al.  Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  S Lovestone,et al.  GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila , 2004, Molecular Psychiatry.

[41]  R. Wyman,et al.  Motor outputs of giant nerve fiber in Drosophila. , 1980, Journal of neurophysiology.

[42]  M. Bianchi,et al.  Functional Studies of Shaggy/Glycogen Synthase Kinase 3 Phosphorylation Sites in Drosophila melanogaster , 2004, Molecular and Cellular Biology.

[43]  B. Hyman,et al.  Transgenic models of Alzheimer’s disease: Learning from animals , 2005, NeuroRX.

[44]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[45]  K. White,et al.  A Drosophila gene encoding a protein resembling the human beta-amyloid protein precursor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[46]  G. Drewes,et al.  Glycogen synthase kinase‐3 and the Alzheimer‐like state of microtubule‐associated protein tau , 1992, FEBS letters.

[47]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[48]  A. Joutel,et al.  Notch signalling pathway and human diseases. , 1998, Seminars in cell & developmental biology.

[49]  E. Kinoshita,et al.  Phosphate-binding Tag, a New Tool to Visualize Phosphorylated Proteins*S , 2006, Molecular & Cellular Proteomics.

[50]  G. Drewes,et al.  MARK, a Novel Family of Protein Kinases That Phosphorylate Microtubule-Associated Proteins and Trigger Microtubule Disruption , 1997, Cell.

[51]  Ann-Shyn Chiang,et al.  Dissecting the pathological effects of human Aβ40 and Aβ42 in Drosophila: A potential model for Alzheimer's disease , 2004 .

[52]  F. van Leuven,et al.  Glycogen synthase kinase‐3β, or a link between amyloid and tau pathology? , 2008, Genes, brain, and behavior.

[53]  P. Lochhead,et al.  A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation. , 2006, Molecular cell.

[54]  Ronald L. Davis,et al.  Spatiotemporal Gene Expression Targeting with the TARGET and Gene-Switch Systems in Drosophila , 2004, Science's STKE.

[55]  S. Younkin,et al.  The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation , 2001, Nature Neuroscience.

[56]  D. Gubb,et al.  Intraneuronal Abeta, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer's disease. , 2005, Neuroscience.

[57]  Ehud Cohen,et al.  Opposing Activities Protect Against Age-Onset Proteotoxicity , 2006, Science.

[58]  David H. Cribbs,et al.  Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.

[59]  J. Melchor,et al.  The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. , 2003, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[60]  N. Mivechi,et al.  Glycogen Synthase Kinase 3β and Extracellular Signal-Regulated Kinase Inactivate Heat Shock Transcription Factor 1 by Facilitating the Disappearance of Transcriptionally Active Granules after Heat Shock , 1998, Molecular and Cellular Biology.

[61]  T. Saido,et al.  Metabolic Regulation of Brain Aβ by Neprilysin , 2001, Science.

[62]  F. LaFerla,et al.  Genetically augmenting tau levels does not modulate the onset or progression of Aβ pathology in transgenic mice , 2007, Journal of neurochemistry.

[63]  M. Konsolaki,et al.  A model for studying Alzheimer's Aβ42-induced toxicity in Drosophila melanogaster , 2004, Molecular and Cellular Neuroscience.

[64]  S. Lovestone,et al.  Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice , 2009, Biochemical and biophysical research communications.

[65]  K. Walsh,et al.  Intraneuronal β-Amyloid Expression Downregulates the Akt Survival Pathway and Blunts the Stress Response , 2005, The Journal of Neuroscience.

[66]  I. Hakker,et al.  Overexpression of Neprilysin Reduces Alzheimer Amyloid-β42 (Aβ42)-induced Neuron Loss and Intraneuronal Aβ42 Deposits but Causes a Reduction in cAMP-responsive Element-binding Protein-mediated Transcription, Age-dependent Axon Pathology, and Premature Death in Drosophila* , 2008, Journal of Biological Chemistry.

[67]  J. Lucas,et al.  Tau-knockout mice show reduced GSK3-induced hippocampal degeneration and learning deficits , 2010, Neurobiology of Disease.

[68]  Ann-Shyn Chiang,et al.  Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[69]  Matthew P. Frosch,et al.  Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[70]  Richard M. Page,et al.  Intraneuronal Aβ, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer’s disease , 2005, Neuroscience.

[71]  J. C. Hall,et al.  Identification of a cholinergic synapse in the giant fiber pathway of Drosophila using conditional mutations of acetylcholine synthesis. , 1984, Journal of neurogenetics.

[72]  E. Masliah,et al.  Neuroprotective Effects of Regulators of the Glycogen Synthase Kinase-3β Signaling Pathway in a Transgenic Model of Alzheimer's Disease Are Associated with Reduced Amyloid Precursor Protein Phosphorylation , 2007, The Journal of Neuroscience.

[73]  J. Melchor,et al.  The Tissue Plasminogen Activator-Plasminogen Proteolytic Cascade Accelerates Amyloid-β (Aβ) Degradation and Inhibits Aβ-Induced Neurodegeneration , 2003, The Journal of Neuroscience.

[74]  W. Noble,et al.  Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. , 2009, Trends in molecular medicine.

[75]  D. Selkoe,et al.  Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death , 2003, Neuron.

[76]  Colin L Masters,et al.  Aβ aggregation and possible implications in Alzheimer's disease pathogenesis , 2009, Journal of cellular and molecular medicine.

[77]  C. Strambi,et al.  Decreasing Glutamate Buffering Capacity Triggers Oxidative Stress and Neuropil Degeneration in the Drosophila Brain , 2004, Current Biology.

[78]  M. Ruberg,et al.  A Conditional Pan-Neuronal Drosophila Model of Spinocerebellar Ataxia 7 with a Reversible Adult Phenotype Suitable for Identifying Modifier Genes , 2007, The Journal of Neuroscience.

[79]  D. Geschwind,et al.  Human Wild-Type Tau Interacts with wingless Pathway Components and Produces Neurofibrillary Pathology in Drosophila , 2002, Neuron.

[80]  Patrick R Hof,et al.  Diet‐induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[81]  M. Bourouis Targeted increase in shaggy activity levels blocks wingless signaling , 2002, Genesis.

[82]  L. Hersh,et al.  Amyloid-β peptide levels in brain are inversely correlated with insulysin activity levels in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[83]  F. Liu,et al.  Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. , 2004, Biochemistry.

[84]  Kit-Yi Leung,et al.  Novel Phosphorylation Sites in Tau from Alzheimer Brain Support a Role for Casein Kinase 1 in Disease Pathogenesis* , 2007, Journal of Biological Chemistry.

[85]  Barry Ganetzky,et al.  On the relationship between senescence and age-related changes in two wild-type strains of Drosophila melanogaster , 1978, Experimental Gerontology.

[86]  D. Nanopoulos,et al.  Learning and memory deficits upon TAU accumulation in Drosophila mushroom body neurons. , 2004, Learning & memory.

[87]  Damian C Crowther,et al.  A Drosophila model of Alzheimer's disease. , 2006, Methods in enzymology.

[88]  U. Wagner,et al.  Tau phosphorylation in transgenic mice expressing glycogen synthase kinase‐3β transgenes , 1997, Neuroreport.

[89]  D. Shepherd,et al.  A comparison of the neuronal dysfunction caused by Drosophila tau and human tau in a Drosophila model of tauopathies , 2007, Invertebrate Neuroscience.